

# Harry Moultrie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2261218/publications.pdf>

Version: 2024-02-01

62  
papers

4,616  
citations

159585  
30  
h-index

123424  
61  
g-index

66  
all docs

66  
docs citations

66  
times ranked

5514  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 496-506.	9.1	53
2	Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. <i>Lancet</i> , The, 2022, 399, 437-446.	13.7	818
3	Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. <i>New England Journal of Medicine</i> , 2022, 386, 494-496.	27.0	570
4	Effectiveness of the Ad26.COVS.2 vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. <i>Lancet</i> , The, 2022, 399, 1141-1153.	13.7	51
5	Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. <i>Science</i> , 2022, 376, eabn4947.	12.6	651
6	The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 603-622.	10.7	99
7	Effectiveness of Ad26.COVS.2 and BNT162b2 Vaccines against Omicron Variant in South Africa. <i>New England Journal of Medicine</i> , 2022, 386, 2243-2245.	27.0	65
8	Safety evaluation of the single-dose Ad26.COVS.2 vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. <i>PLoS Medicine</i> , 2022, 19, e1004024.	8.4	10
9	Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab040.	0.9	27
10	A position statement and practical guide to the use of particulate filtering facepiece respirators (N95), Tj ETQq0 0 0 rgBT /Overlock 10 T Mycobacterium tuberculosis and SARS-CoV-2. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2021, 26, .	0.6	5
11	Advancing TB research using digitized programmatic data. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 890-895.	1.2	1
12	A geospatial analysis of two-hour surgical access to district hospitals in South Africa. <i>BMC Health Services Research</i> , 2020, 20, 744.	2.2	4
13	Evaluation of the intensified tuberculosis case finding guidelines for children living with HIV. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 1322-1328.	1.2	9
14	Alcohol use and sexual risk behaviour among men and women in inner-city Johannesburg, South Africa. <i>BMC Public Health</i> , 2017, 17, 548.	2.9	33
15	Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. <i>PLoS ONE</i> , 2017, 12, e0186557.	2.5	52
16	Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa. <i>Frontiers in Microbiology</i> , 2016, 7, 1947.	3.5	20
17	Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children. <i>Pediatric Pulmonology</i> , 2016, 51, 157-164.	2.0	17
18	CHAPAS-3 fills the gap. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 133-134.	9.1	2

#	ARTICLE	IF	CITATIONS
19	Growth in Virologically Suppressed HIV-Positive Children on Antiretroviral Therapy. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e254-e259.	2.0	3
20	Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 543-549.	3.0	42
21	Virologic Failure Among Children Taking Lopinavir/Ritonavir-containing First-line Antiretroviral Therapy in South Africa. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 175-179.	2.0	20
22	Outcomes in treatment with darunavir/ritonavir in ART-experienced paediatric patients. <i>South African Medical Journal</i> , 2015, 105, 330.	0.6	2
23	Focus on adolescents with HIV and AIDS. <i>South African Medical Journal</i> , 2014, 104, 897.	0.6	11
24	Virologic Response in Children Treated With Abacavir-compared With Stavudine-based Antiretroviral Treatment. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 617-622.	2.0	29
25	Tuberculosis Immune Reconstitution Inflammatory Syndrome in Children Initiating Antiretroviral Therapy for HIV Infection. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 499-503.	2.0	25
26	Prognosis of Children With HIV-1 Infection Starting Antiretroviral Therapy in Southern Africa. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 608-616.	2.0	24
27	Viral load versus CD4+ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa. <i>Aids</i> , 2014, 28, 2451-2460.	2.2	12
28	Predictors of Virologic and Clinical Response to Nevirapine versus Lopinavir/Ritonavir-based Antiretroviral Therapy in Young Children With and Without Prior Nevirapine Exposure for the Prevention of Mother-to-child HIV Transmission. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 846-854.	2.0	16
29	The Effect of Tuberculosis Treatment on Virologic and Immunologic Response to Combination Antiretroviral Therapy Among South African Children. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 136-144.	2.1	5
30	Novel biomarkers for paediatric tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 900-901.	9.1	1
31	Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 676-681.	1.2	5
32	Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa. <i>Tropical Medicine and International Health</i> , 2013, 18, 194-198.	2.3	20
33	Cost and outcomes of paediatric antiretroviral treatment in South Africa. <i>Aids</i> , 2013, 27, 243-250.	2.2	23
34	Immune Recovery After Starting ART in HIV-Infected Patients Presenting and Not Presenting With Tuberculosis in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, 142-145.	2.1	21
35	A survey of paediatric HIV programmatic and clinical management practices in Asia and sub-Saharan Africa—the International epidemiologic Databases to Evaluate AIDS (IeDEA). <i>Journal of the International AIDS Society</i> , 2013, 16, 17998.	3.0	37
36	When to Start Antiretroviral Therapy in Children Aged 2–5 Years: A Collaborative Causal Modelling Analysis of Cohort Studies from Southern Africa. <i>PLoS Medicine</i> , 2013, 10, e1001555.	8.4	32

#	ARTICLE	IF	CITATIONS
37	Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. <i>Aids</i> , 2013, 27, 1933-1940.	2.2	48
38	Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. <i>Aids</i> , 2013, 27, 781-785.	2.2	22
39	Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa. <i>Global Health Action</i> , 2013, 6, 19248.	1.9	36
40	Temporal Trends in the Characteristics of Children at Antiretroviral Therapy Initiation in Southern Africa: The leDEA-SA Collaboration. <i>PLoS ONE</i> , 2013, 8, e81037.	2.5	36
41	Variability of Growth in Children Starting Antiretroviral Treatment in Southern Africa. <i>Pediatrics</i> , 2012, 130, e966-e977.	2.1	46
42	Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children. <i>New England Journal of Medicine</i> , 2012, 366, 2380-2389.	27.0	172
43	The Contribution of Maternal HIV Seroconversion During Late Pregnancy and Breastfeeding to Mother-to-Child Transmission of HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 417-425.	2.1	129
44	Effect of Baseline Immune Suppression on Growth Recovery in HIV Positive South African Children Receiving Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 235-242.	2.1	10
45	Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 428-437.	2.1	119
46	Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 273-277.	2.0	24
47	The Effect of Early Initiation of Antiretroviral Treatment in Infants on Pediatric AIDS Mortality in South Africa. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 474-480.	2.0	46
48	The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure. <i>Tropical Medicine and International Health</i> , 2012, 17, 1386-1390.	2.3	9
49	Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe. <i>Clinical Infectious Diseases</i> , 2012, 55, 1707-1718.	5.8	68
50	Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. <i>Journal of the International AIDS Society</i> , 2012, 15, 5-5.	3.0	34
51	A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa. <i>Journal of the International AIDS Society</i> , 2011, 14, 7-7.	3.0	23
52	Antiretroviral Therapy Responses Among Children Attending a Large Public Clinic in Soweto, South Africa. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 974-979.	2.0	50
53	Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africa—The leDEA Southern Africa Collaboration. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 270-278.	2.1	112
54	Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy — The leDEA Southern Africa Collaboration. <i>Tropical Medicine and International Health</i> , 2011, 16, 1367-1371.	2.3	21

#	ARTICLE	IF	CITATIONS
55	Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment. PLoS ONE, 2011, 6, e17273.	2.5	35
56	Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. Aids, 2010, 24, 1341-1349.	2.2	41
57	Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 524-532.	2.1	88
58	Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. Aids, 2010, 24, 139-146.	2.2	33
59	Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the leDEA Southern Africa collaboration. South African Medical Journal, 2009, 99, 653-60.	0.6	44
60	Outcomes of the South African National Antiretroviral Treatment Programme for children: the leDEA Southern Africa collaboration. South African Medical Journal, 2009, 99, 730-7.	0.6	93
61	Protective Effect of HIV-Positive Primary Caregivers on Mortality in Children Receiving Antiretroviral Therapy?. Journal of Infectious Diseases, 2008, 198, 939-940.	4.0	1
62	Challenges to Pediatric HIV Care and Treatment in South Africa. Journal of Infectious Diseases, 2007, 196, S474-S481.	4.0	94